<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179435</url>
  </required_header>
  <id_info>
    <org_study_id>C19-11</org_study_id>
    <secondary_id>2019-A00992-55</secondary_id>
    <nct_id>NCT04179435</nct_id>
  </id_info>
  <brief_title>Cognitive and Brain Development in Adolescents With Gilles de la Tourette Syndrome</brief_title>
  <acronym>CADETS</acronym>
  <official_title>Développement Cognitif et cérébral Chez Les Adolescents Souffrants d'un Syndrome de Gilles de la Tourette</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In children with neurodevelopmental disorders, adolescence is usually associated with a
      reshaping of the clinical picture and symptomatology. Tourette syndrome (TS) is a paradigmal
      neurodevelopmental syndrome characterised by involuntary paroxysmal movements (motor tics)
      and vocalisation (vocal tics) often associated with various psychiatric disorders. The
      neuronal and cognitive mechanisms associated with TS symptoms improvement during adolescence,
      or the persistence in adulthood remains unknown, and this is what we aim to address in this
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thus, the aims of the present project is threefold:

      Aim 1: To evaluate the maturation of cognitive functions in adolescents with TS compared to
      typically developing adolescents.

      To achieve this aim, three distinct cognitive dimensions will be assessed in all subjects
      (patients and controls): (i) reward sensitivity and habit formation; (ii) cognitive
      impulsivity and action control and (iii) self-agency.

      Aim 2: To identify neuronal correlates of cognitive function and brain development in health
      and disease. To achieve this aim, we will use a combined behavioural (as described in Aim 1),
      (i) neuroimaging and (ii) TMS approaches.

      Aim 3: To predict clinical outcome . In this part of the project we aim to identify
      behavioural, imaging or neurophysiological markers of clinical outcome in patients with TS.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Between group comparison</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral test main outcome measures [1]</measure>
    <time_frame>from 16 to 20 months</time_frame>
    <description>reaction times</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral test main outcome measures [2]</measure>
    <time_frame>from 16 to 20 months</time_frame>
    <description>discounting factor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral test main outcome measures [3]</measure>
    <time_frame>from 16 to 20 months</time_frame>
    <description>number of premature responses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral test main outcome measures [4]</measure>
    <time_frame>from 16 to 20 months</time_frame>
    <description>agency composite scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI scan measures</measure>
    <time_frame>from 16 to 20 months</time_frame>
    <description>whole brain structural connectivity, whole brain functional connectivity, brain cortical and subcortical structures volumes and morphology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcranial magnetic stimulation</measure>
    <time_frame>from 16 to 20 months</time_frame>
    <description>intracortical inhibition (SICI) scores</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Tourette Syndrome in Adolescence</condition>
  <arm_group>
    <arm_group_label>Tourette syndrome</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral testing on cognitive computerized tasks</intervention_name>
    <description>Testing on cognitive computerized tasks</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Tourette syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>brain MRI</intervention_name>
    <description>Brain MRI scans</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Tourette syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TMS</intervention_name>
    <description>Measure of the cortical inhibitory capacity using TMS measures</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Tourette syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tourette syndrome

          -  Ages 13 - 18

          -  Acceptance to perform the Brain MRI

          -  Acceptance to perform the cognitive testing

          -  Acceptance to perform the TMS measures

        Exclusion Criteria:

          -  Learning disability

          -  Incompatibility with MRI procedure (metal body implants, pregnancy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Worbe Yulia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Worbe Yulia, MD, PhD</last_name>
    <phone>+ 33 1 57 43 55</phone>
    <email>Yulia.worbe@aphp.fr</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

